|Bid||5.96 x 1000|
|Ask||5.96 x 1800|
|Day's range||5.79 - 6.32|
|52-week range||4.02 - 43.12|
|Beta (5Y monthly)||1.62|
|PE ratio (TTM)||N/A|
|Earnings date||27 Feb 2023 - 03 Mar 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||8.77|
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Fate Therapeutics...
Fate Therapeutics (FATE) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
FATE decides not to continue its collaboration and option agreement with Janssen. The company also conducts a strategic review.